AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
Stocks in this Quantisnow insightHealth Care
Historical context for AIM
Across the 27 sessions after earlier AIM headlines, the stock closed higher 11 times and lower 16 times, with a median move of 6.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AIM | SPY |
|---|---|---|---|
| May 8, 2026 | AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds | -39.7% | +0.8% |
| May 7, 2026 | AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential | +16.4% | -0.3% |
| Apr 16, 2026 | AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP | +3.0% | +0.2% |
| Apr 14, 2026 | AIM ImmunoTech Provides Routine Update on Annual Filings | +8.9% | +1.2% |
| Apr 9, 2026 | AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event | -6.2% | +0.6% |
| Mar 18, 2026 | AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors | +43.7% | -1.4% |
Quantisnow market dataAMEX
AIM
AIM ImmunoTech Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for AIM
Full AIM profile on Quantisnow Follow AIM and get a push notification the moment its next story breaks.